Plasma Biomarker in Amblyopia Patients

Recruiting now

Conditions studied: Amblyopia

In brief

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Key facts

Study ID

NCT05705778

Run by

Zhongshan Ophthalmic Center, Sun Yat-sen University

People needed

600

Starts

2022-11-01

Expected to finish

2027-10-31

Last updated by the study team

2023-01-31

Who can join

Age: 3 and older, up to 12. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosed with amblyopia
• 3-12 years of age
• Able to tolerate amblyopia treatment
• Agree to be involved in this study and agree to have a follow up visit every 3 months.

You may not qualify if…

• Have previous treatment history before
• Have pathological ocular anomalies known to cause reduced visual acuity
• Have previous psychiatric, visual or neurological disorders
• Have eccentric fixation and/or abnormal retinal correspondence
• Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Where it is running

• Zhongshan Ophthalmic Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.